Charmacy Pharmaceutical Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Charmacy Pharmaceutical te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Healthcare winstgroei	21.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Charmacy Pharmaceutical onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

SEHK:2289 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	4,482	52	-63	-42	N/A
3/31/2024	4,443	52	-100	-69	N/A
12/31/2023	4,404	51	-137	-97	N/A
9/30/2023	4,480	74	-163	-125	N/A
6/30/2023	4,557	96	-190	-153	N/A
3/31/2023	4,366	93	-77	-55	N/A
12/31/2022	4,175	90	35	44	N/A
9/30/2022	3,931	54	44	51	N/A
6/30/2022	3,688	18	53	59	N/A
3/31/2022	3,741	20	4	20	N/A
12/31/2021	3,794	23	-45	-20	N/A
9/30/2021	3,959	29	75	111	N/A
6/30/2021	4,124	36	195	241	N/A
3/31/2021	4,058	38	137	186	N/A
12/31/2020	3,992	41	79	131	N/A
9/30/2020	3,819	35	-100	-37	N/A
6/30/2020	3,645	29	-280	-205	N/A
3/31/2020	3,569	34	-175	-101	N/A
12/31/2019	3,493	40	-70	4	N/A
9/30/2019	3,557	41	-31	44	N/A
6/30/2019	3,621	42	7	84	N/A
3/31/2019	3,778	44	-21	66	N/A
12/31/2018	3,935	45	-49	49	N/A
9/30/2018	4,075	46	-122	6	N/A
6/30/2018	4,214	47	-196	-37	N/A
3/31/2018	4,155	46	N/A	-35	N/A
12/31/2017	4,096	45	N/A	-33	N/A
9/30/2017	3,946	54	N/A	-82	N/A
6/30/2017	3,796	63	N/A	-130	N/A
3/31/2017	3,733	60	N/A	-116	N/A
12/31/2016	3,670	56	N/A	-102	N/A
9/30/2016	3,605	47	N/A	-27	N/A
6/30/2016	3,540	38	N/A	47	N/A
3/31/2016	3,468	32	N/A	120	N/A
12/31/2015	3,397	26	N/A	194	N/A
9/30/2015	3,299	31	N/A	156	N/A
6/30/2015	3,200	35	N/A	119	N/A
3/31/2015	3,107	36	N/A	52	N/A
12/31/2014	3,014	36	N/A	-15	N/A
12/31/2013	2,401	22	N/A	45	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van 2289 boven de spaarquote ( 2.3% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van 2289 naar verwachting sneller zal groeien dan de markt Hong Kong

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van 2289 naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van 2289 naar verwachting sneller zal groeien dan de markt Hong Kong.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van 2289 naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 2289 naar verwachting over 3 jaar hoog zal zijn

Charmacy Pharmaceutical Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Charmacy Pharmaceutical Co., Ltd. Provides Financial Guidance for the 11 Months Ended 30 November 2022

Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021

Recent updates

Investor sentiment improves as stock rises 17%

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 1H 2023)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 34%

Upcoming dividend of CN¥0.30 per share

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

New major risk - Share price stability

Investor sentiment improves as stock rises 41%

New major risk - Financial position

Charmacy Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 10 July 2024

Charmacy Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 18%

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 31%

Investor sentiment improves as stock rises 19%

New major risk - Earnings quality

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

First half 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.19 in 1H 2022)

Investor sentiment improves as stock rises 23%

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Upcoming dividend of HK$0.50 per share at 6.0% yield

Charmacy Pharmaceutical Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Charmacy Pharmaceutical Co., Ltd. Announces Board Changes

Upcoming dividend of CN¥0.45 per share at 6.2% yield

Charmacy Pharmaceutical Co., Ltd. Announces Ordinary Final Dividend for the Year Ended 31 December 2022, Payable on July 31, 2023

Charmacy Pharmaceutical Co., Ltd. Provides Financial Guidance for the 11 Months Ended 30 November 2022

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.24 in 1H 2021)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2022 Results on Aug 31, 2022

Charmacy Pharmaceutical Co., Ltd. Announces Executive Changes

Investor sentiment improved over the past week

Insufficient new directors

Charmacy Pharmaceutical Co., Ltd. Announces Change in Board of Directors and Composition of Board Committees

Full year 2021 earnings released

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022

Investor sentiment deteriorated over the past week

Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

Charmacy Pharmaceutical Co., Ltd. to Distribute the Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of CN¥0.20 per share

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

Full year 2020 earnings released: EPS CN¥0.38 (vs CN¥0.37 in FY 2019)

Full year 2020 earnings released

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: HK$4.40

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

New 90-day low: HK$4.43

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Investor sentiment improved over the past week

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

First half earnings released

New 90-day low: HK$4.49

First half earnings released

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

New 90-day low - HK$5.12

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven